Navigation Links
KaloBios to Present at BioCentury's NewsMakers in the Biotech Industry Conference

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will present at the BioCentury NewsMakers in the Biotech Industry Conference on September 27 at the Millennium Broadway Hotel & Conference Center in New York City. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.


Company Presentation:
When: Friday, September 27, 2013, 11:00 AM EDT
Where: Millennium Broadway Hotel & Conference Center, New York City, NY

To access the live and archived audio webcast of the NewsMakers presentation, please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab:

A replay of the webcast will be available one hour after the conclusion of the live event. 

About KaloBios
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer.  For more information on KaloBios Pharmaceuticals, please visit our web site at


Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146

Media Contact:

Joan E. Kureczka
Kureczka/Martin Associates
Tel:  (415) 821-2413
Mobile: (415) 690-0210

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. KaloBios Announces Retirement Of Chief Financial Officer
2. KaloBios Appoints Donald R. Joseph as Chief Legal Officer
3. U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios Novel Biologic Candidate for Pseudomonas aeruginosa
4. KaloBios Announces Fiscal Year 2012 Financial Results
5. GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
6. AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas
7. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
8. MEI Pharma to Present at BioCenturys NewsMakers in the Biotech Industry Conference
9. RXi Pharmaceuticals to Present at the 12th Annual BIO Investor Forum
10. Bone Biologics Investor Presentation Now Available for On-demand Viewing at
11. San Francisco Business Times Presents: Richmond! Your Home Front for Business
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
Breaking Biology Technology:
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):